InterCure Ltd.
INCRHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframePart of the healthcare sector, InterCure Ltd. (INCR) is listed under Drug Manufacturers - Specialty & Generic. The $81.3M market capitalization puts INCR squarely in micro-cap range for its industry. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Market Cap
$81.3M
Beta
0.59
P/E (TTM)
—
P/E (Fwd)
-3.66
EPS (TTM)
$-1.11
EPS (Fwd)
$-1.48
ROE
-9.3%
ROA
-5.8%
Cash
—
Total Debt
—
Free CF
-$37.4M
52W Change
-35.3%
Annual Financials
Cash vs Debt
Where INCR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, INCR finished 373.68% above its 150-day moving average ($1.14) and 369.57% above its 200-day moving average ($1.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INCR overbought or oversold?
At the September 3, 2026 close, INCR's RSI(14) was 87.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company is burning cash, with free cash flow at -$37.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -9.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $388.7M (2022) to $270.2M (2025), a 30% decline worth watching.
The relatively low beta of 0.59 suggests INCR is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence InterCure Ltd.'s trajectory.